Recent

% | $
Quotes you view appear here for quick access.

Seattle Genetics, Inc. Message Board

  • mauihope2000 mauihope2000 Nov 4, 2013 2:17 PM Flag

    Will Adcetris revenue increase?

    Will the new guidelines which allow for longer duration make a difference? I want to see Adcetris revenue above $40ml. Without a boost it looks like revenue will be range bound near the $130-$140ml for at least another year. I'm also seeing new collaboration deals slowing compared to past activity. I believe it's been just one this year. SGEN is no longer the only game in town. There is still years before frontline or B cell approvals. Those will be the major movers. For now I believe the analysis estimates are right on.
    Just my own worthless opinion.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • When you say "no longer the only game in town," are you referring to IMGN's ADC linker technology? Just curious to know if you have any real insights into the differences in the technology. Seems like SGEN is executing very well on a broad-based strategy. Adcetris looks to be the showcase model for future things to come.

 
SGEN
48.93+0.87(+1.81%)Jul 28 4:00 PMEDT